Press release


  Biomarkers for personalised breast cancer treatment 

New Methods Improve Breast Cancer Therapy,
presented at the San Antonio Breast Cancer Symposium in Texas, USA, 2013



New network topology approaches reveal differential correlation patterns in breast cancer. BMC Systems Biology 2013 Aug 15;7:78. doi:  10.1186/1752-0509-7-78

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer - A Substudy of the Neoadjuvant GeparQuinto Trial. PLoS One. 2013; 8(12): e79775. doi: 10.1371/journal.pone.0079775

The immunogenicity of breast cancer--molecular subtypes matter. Ann Oncol (2014) 25 (8): 1453-1455. doi: 10.1093/annonc/mdu235

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol (2014) 25 (8): 1544-1550. doi: 10.1093/annonc/mdu112

PIK3CA mutations are associated with lower rates of pathological complete response (pCR) to anti-HER2 therapy in primary HER2-overexpressing breast cancer. J Clin Oncol. 2014 Oct 10;32(29): 3212-20. doi: 10.1200/JCO.2014.55.7876.

Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. Pharmacoeconomics. 2015; 33: 179–190. doi:  10.1007/s40273-014-0227-x

 Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. Ann Oncol (2015) 26 (1): 95-100.doi: 10.1093/annonc/mdu487

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol (2015) 26 (2): 259-271.doi: 10.1093/annonc/mdu450

 Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers. J Clin Oncol. 2015 Mar 20;33(9): 983-91. doi: 10.1200/JCO.2014.58.1967


RESPONSIFY partners' presentations on Breast Cancer at ASCO , 2014




The RESPONSIFY Flyer is available on request

Please contact tp21.